PROTOKINETIX BLOG

Find out how AAGP® is changing lives through cell survival

As we move forward with clinical research for our anti-aging glycopeptide, AAGP®, we continue to uncover new areas of opportunity for the molecule. See how AAGP® is helping to provide more hope for patients and investors in the areas of ophthalmology, transplants, dermatology and biomanufacturing.

Category:
Sort By:
Apr 26, 2016
Apr 26, 2016

byncaipen

Transplants

St. Marys, West Virginia ProtoKinetix, Incorporated (OTCQB: PKTX) (the “Company” or “ProtoKinetix”) (www.protokinetix.com) outlines the steps to be completed for the application to conduct a clinical trial in Canada. For the last four years ProtoKinetix has been involved in a collaboration with the Laboratory of Dr. James Shapiro, M.D., Ph.D., FRCSC, the director of the...Read more

Subscribe for updates

Get alerts about company news and key findings directly in your inbox.

Request More Information

Talk to a member of the ProtoKinetix team to learn more about our research and results.

Picture of a molecule
Picture of a molecule